Novavax enlists AGC Biologics to manufacture adjuvant for COVID-19 shot
Novavax is racing against some of the world’s biggest pharmaceutical companies in its COVID-19 vaccine effort, and the biotech has now brought on a partner to manufacture its adjuvant.
The company
enlisted Japanese contract development and manufacturing organization AGC Biologics to scale up and produce its Matrix-M adjuvant, a component of the novel coronavirus vaccine candidate NVX-CoV2373.
The partners aim to deliver vaccine doses in 2020 and 2021, AGC says.
AGC
is working to “quickly” ramp up the adjuvant supply amid the pandemic, CEO Patricio Massera said in a statement,
adding that the urgency “could not be higher.”
FiercePharma